The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Prevalence of Age-Related Macular Degeneration in the US in 2019
Open accessAbstract
Importance: Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness. AMD prevalence has not been estimated for the US in over a decade and early-stage AMD prevalence estimates are scarce and inconsistently measured. Objective: To produce estimates of early- and late-stage AMD prevalence overall and by age, gender, race and ethnicity, county, and state. Design, Setting, and Participants: The study team conducted a bayesian meta-regression analysis of relevant data sources containing information on the prevalence of AMD among different population groups in the US. Data Sources: We included data from the American Community Survey (2019), the National Health and Nutrition Examination Survey (2005-2008), US Centers for Medicare & Medicaid Services claims for fee-for-service beneficiaries (2018), and population-based studies (2004-2016). Study Selection: We included all relevant data from the US Centers for Disease Control and Prevention’s Vision and Eye Health Surveillance System. Data Extraction and Synthesis: The prevalence of early- and late-stage AMD was estimated and stratified when possible by factors including county, age group, gender, and race and ethnicity. Data analysis occurred from June 2021 to April 2022. Main Outcomes or Measures: The prevalence of early- (defined as retinal pigment epithelium abnormalities or the presence of drusen 125 or more microns in diameter in either eye) and late-stage (defined as choroidal neovascularization and/or geographic atrophy in either eye) manifestations of AMD. Results: This study used data from nationally representative and local population-based studies that represent the populations in which they were conducted. For 2019, we estimated that there were 18.34 million people 40 years and older (95% uncertainty interval [UI], 15.30-22.03) living with early-stage AMD, corresponding to a crude prevalence rate of 11.64% (95% UI, 9.71-13.98). We estimated there were 1.49 million people 40 years and older (95% UI, 0.97-2.15) living with late-stage AMD, corresponding to a crude prevalence rate of 0.94% (95% UI, 0.62-1.36). Prevalence rates of early- and late-stage AMD varied by demographic characteristics and geography. Conclusions and Relevance: We estimated a higher prevalence of early-stage AMD and a similar prevalence of late-stage AMD as compared with earlier studies. State-level and county-level AMD estimates may help guide public health practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steinmetz, J. D., Bourne, R. R. A., Briant, P. S., Flaxman, S. R., Taylor, H. R. B., Jonas, J. B., Abdoli, A. A., Abrha, W. A., Abualhasan, A., Abu-Gharbieh, E. G., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30489-7 · Cited by 3,189
Self-citationPrevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Causes and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
Clinical Classification of Age-related Macular Degeneration
Ferris, F. L., Wilkinson, C. P., Bird, A., Chakravarthy, U., Chew, E., Csaky, K., & Sadda, S. R. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.036 · Cited by 1,863
National Health and Nutrition Examination Survey
(2008) · Encyclopedia of Epidemiology · doi:10.4135/9781412953948.n305 · Cited by 1,342
Prevalence of Age-Related Macular Degeneration in the US Population
Klein, R. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.318 · Cited by 514
Rudnicka, A. R., Jarrar, Z., Wormald, R., Cook, D. G., Fletcher, A., & Owen, C. G. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.09.027 · Cited by 394
Age-Related Macular Degeneration Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A., Lim, J. I., Vemulakonda, G. A., & Ying, G.-S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.024 · Cited by 349
Rein, D. B. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.58 · Cited by 344
Self-citation
Research works printed but not linked: 2
- Varma, 2016, Prevalence and causes of visual impairment and blindness in Chinese American adults: the Chinese American eye study., JAMA Ophthalmol, 785, 10.1001/jamaophthalmol.2016.1261 · doi:10.1001/jamaophthalmol.2016.1261
- Flaxman, 2015, An Integrative Metaregression Framework for Descriptive Epidemiology
Cited by
Age-Related Macular Degeneration: A Review
Fleckenstein, M., Schmitz-Valckenberg, S., & Chakravarthy, U. (2024) · JAMA · doi:10.1001/jama.2023.26074 · Cited by 549
Haldrup, S. H., Fabian-Jessing, B. K., Jakobsen, T. S., Lindholm, A. B., Adsersen, R. L., Aagaard, L., Bek, T., Askou, A. L., & Corydon, T. J. (2024) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2024.101242 · Cited by 18
Poulsen, K., Hanna, K., Nieves, J., Nguyen, N., Sharma, P., Grishanin, R., Corbau, R., & Kiss, S. (2025) · Molecular Therapy Methods & Clinical Development · doi:10.1016/j.omtm.2025.101430 · Cited by 8
Metadata
- Authors
- Rein, D. B., Wittenborn, J. S., Burke-Conte, Z., Gulia, R., Robalik, T., Ehrlich, J. R., Lundeen, E. A., & Flaxman, A. D.
- Venue
- JAMA Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 2022-12-01
- Volume
- 140
- Issue
- 12
- Pages
- 1202
- ISSN
- 2168-6165 (ISSN-L)
- OpenAlex
- W4308056499
- Cited by
- 275
- References
- 19
- FWCI
- 39.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of Age-Related Macular Degeneration in the US in 2019. https://app.cochat.ai/papers/10.1001/jamaophthalmol.2022.4401
- The paper
- Rein, D. B., Wittenborn, J. S., Burke-Conte, Z., Gulia, R., Robalik, T., Ehrlich, J. R., Lundeen, E. A., & Flaxman, A. D. (2022). Prevalence of Age-Related Macular Degeneration in the US in 2019. JAMA Ophthalmology. https://doi.org/10.1001/jamaophthalmol.2022.4401
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.